Cyxone announces issuance of U.S. divisional patent for drug candidate T20K in MS
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,159,710 B2 – a divisional patent related to the already approved ‘parent patent’ for drug candidate T20K in development for the treatment of multiple sclerosis (MS).The newly issued U.S. divisional patent is a sub-patent to the granted patent titled Cyclotides as immunosuppressive agents (US 9,453,052 B2). As stated in the application, this divisional patent relates to using the cyclotide-based drug candidate T20K in a pharmaceutical